AU2014361728A1 - Apparatus for producing therapeutically active proteins in blood and uses thereof - Google Patents
Apparatus for producing therapeutically active proteins in blood and uses thereof Download PDFInfo
- Publication number
- AU2014361728A1 AU2014361728A1 AU2014361728A AU2014361728A AU2014361728A1 AU 2014361728 A1 AU2014361728 A1 AU 2014361728A1 AU 2014361728 A AU2014361728 A AU 2014361728A AU 2014361728 A AU2014361728 A AU 2014361728A AU 2014361728 A1 AU2014361728 A1 AU 2014361728A1
- Authority
- AU
- Australia
- Prior art keywords
- blood sample
- blood
- interleukin
- substrates
- therapeutically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 121
- 239000008280 blood Substances 0.000 title claims abstract description 121
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 55
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 55
- 238000000034 method Methods 0.000 claims abstract description 61
- 239000000758 substrate Substances 0.000 claims abstract description 61
- 239000000463 material Substances 0.000 claims abstract description 36
- 238000003860 storage Methods 0.000 claims abstract description 26
- 150000004760 silicates Chemical class 0.000 claims abstract description 20
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 14
- 210000000601 blood cell Anatomy 0.000 claims abstract description 13
- 108010074328 Interferon-gamma Proteins 0.000 claims description 22
- 102000004388 Interleukin-4 Human genes 0.000 claims description 20
- 108090000978 Interleukin-4 Proteins 0.000 claims description 20
- 102000003814 Interleukin-10 Human genes 0.000 claims description 19
- 108090000174 Interleukin-10 Proteins 0.000 claims description 19
- 230000001225 therapeutic effect Effects 0.000 claims description 19
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 17
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 17
- 102000004889 Interleukin-6 Human genes 0.000 claims description 17
- 108090001005 Interleukin-6 Proteins 0.000 claims description 17
- 102000004890 Interleukin-8 Human genes 0.000 claims description 17
- 108090001007 Interleukin-8 Proteins 0.000 claims description 17
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 17
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 17
- 102000013462 Interleukin-12 Human genes 0.000 claims description 16
- 108010065805 Interleukin-12 Proteins 0.000 claims description 16
- 102000003816 Interleukin-13 Human genes 0.000 claims description 16
- 108090000176 Interleukin-13 Proteins 0.000 claims description 16
- 102000013691 Interleukin-17 Human genes 0.000 claims description 16
- 108050003558 Interleukin-17 Proteins 0.000 claims description 16
- 102000000588 Interleukin-2 Human genes 0.000 claims description 16
- 108010002350 Interleukin-2 Proteins 0.000 claims description 16
- 102000000743 Interleukin-5 Human genes 0.000 claims description 16
- 108010002616 Interleukin-5 Proteins 0.000 claims description 16
- 102000000704 Interleukin-7 Human genes 0.000 claims description 16
- 108010002586 Interleukin-7 Proteins 0.000 claims description 16
- 102000000585 Interleukin-9 Human genes 0.000 claims description 16
- 108010002335 Interleukin-9 Proteins 0.000 claims description 16
- 102000003812 Interleukin-15 Human genes 0.000 claims description 15
- 108090000172 Interleukin-15 Proteins 0.000 claims description 15
- 108060003951 Immunoglobulin Proteins 0.000 claims description 11
- 102000018358 immunoglobulin Human genes 0.000 claims description 11
- 102100023688 Eotaxin Human genes 0.000 claims description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 10
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 10
- 108010082548 Chemokine CCL11 Proteins 0.000 claims description 9
- 102000004127 Cytokines Human genes 0.000 claims description 9
- 108090000695 Cytokines Proteins 0.000 claims description 9
- 229940072221 immunoglobulins Drugs 0.000 claims description 9
- 102100037850 Interferon gamma Human genes 0.000 claims description 8
- 230000001965 increasing effect Effects 0.000 claims description 7
- 201000008482 osteoarthritis Diseases 0.000 claims description 7
- 208000019775 Back disease Diseases 0.000 claims description 6
- -1 lL-7 Proteins 0.000 claims description 6
- 125000000129 anionic group Chemical group 0.000 claims description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 5
- 239000011707 mineral Substances 0.000 claims description 5
- 239000004033 plastic Substances 0.000 claims description 4
- 229920003023 plastic Polymers 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 2
- 239000004952 Polyamide Substances 0.000 claims description 2
- 239000004793 Polystyrene Substances 0.000 claims description 2
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 claims description 2
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims 2
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 claims 2
- 108010055166 Chemokine CCL5 Proteins 0.000 claims 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 2
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 28
- 229940028885 interleukin-4 Drugs 0.000 description 18
- 235000012239 silicon dioxide Nutrition 0.000 description 18
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 17
- 229940076144 interleukin-10 Drugs 0.000 description 17
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 15
- 239000003102 growth factor Substances 0.000 description 15
- 229940100601 interleukin-6 Drugs 0.000 description 15
- 229940100994 interleukin-7 Drugs 0.000 description 15
- 229940096397 interleukin-8 Drugs 0.000 description 15
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 15
- 210000002381 plasma Anatomy 0.000 description 15
- 102000008070 Interferon-gamma Human genes 0.000 description 14
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 14
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 14
- 210000003714 granulocyte Anatomy 0.000 description 14
- 229960003130 interferon gamma Drugs 0.000 description 14
- 229940117681 interleukin-12 Drugs 0.000 description 14
- 229940100602 interleukin-5 Drugs 0.000 description 14
- 229940118526 interleukin-9 Drugs 0.000 description 14
- 230000004936 stimulating effect Effects 0.000 description 14
- 238000011282 treatment Methods 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 11
- 102000000589 Interleukin-1 Human genes 0.000 description 10
- 108010002352 Interleukin-1 Proteins 0.000 description 10
- 239000008187 granular material Substances 0.000 description 9
- 210000003127 knee Anatomy 0.000 description 9
- 239000000377 silicon dioxide Substances 0.000 description 9
- 239000000499 gel Substances 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 7
- 102100021984 C-C motif chemokine 4-like Human genes 0.000 description 7
- 108010055165 Chemokine CCL4 Proteins 0.000 description 7
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 7
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 7
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 7
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 102000009270 Tumour necrosis factor alpha Human genes 0.000 description 7
- 108050000101 Tumour necrosis factor alpha Proteins 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 108010052790 interleukin 1 precursor Proteins 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 238000001056 aerosol solvent extraction system Methods 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 239000005995 Aluminium silicate Substances 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 235000012211 aluminium silicate Nutrition 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 229960000892 attapulgite Drugs 0.000 description 4
- 239000000440 bentonite Substances 0.000 description 4
- 229910000278 bentonite Inorganic materials 0.000 description 4
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 4
- VNSBYDPZHCQWNB-UHFFFAOYSA-N calcium;aluminum;dioxido(oxo)silane;sodium;hydrate Chemical compound O.[Na].[Al].[Ca+2].[O-][Si]([O-])=O VNSBYDPZHCQWNB-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- LRCFXGAMWKDGLA-UHFFFAOYSA-N dioxosilane;hydrate Chemical compound O.O=[Si]=O LRCFXGAMWKDGLA-UHFFFAOYSA-N 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 4
- 229910052625 palygorskite Inorganic materials 0.000 description 4
- 229910052615 phyllosilicate Inorganic materials 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 210000003423 ankle Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 229910052726 zirconium Inorganic materials 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 1
- RSGFPIWWSCWCFJ-VAXZQHAWSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O RSGFPIWWSCWCFJ-VAXZQHAWSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical group Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 206010060820 Joint injury Diseases 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- 208000016593 Knee injury Diseases 0.000 description 1
- 102000013967 Monokines Human genes 0.000 description 1
- 108010050619 Monokines Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 208000024765 knee pain Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/16—Particles; Beads; Granular material; Encapsulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Sustainable Development (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides methods for producing therapeutically active proteins in a blood sample, the method comprising incubating a blood sample in a blood collection or storage device containing one or more substrates, the one or more substrates (a) having a density less than that of erythrocytes and greater than that of plasma and being capable of floating in the blood sample, (b) comprising silicates material or (c) comprising material capable of adhesion to one or more blood cells.
Description
APPARATUS FOR PRODUCING THERAPEUTICALLY ACTIVE PROTEINS IN BLOOD
AND USES THEREOF
FIELD
The present invention relates to apparatus for producing therapeutically active proteins in blood and methods for producing therapeutically active proteins using such apparatus.
BACKGROUND US 6,713,246 and US 6,623,472, assigned to Orthogen Gentechnologic GmbH and Orthogen AG respectively, describe methods for enhancing the production of therapeutically effective proteins, such as interleukin-1 receptor antagonists (IL-1Ra) in blood using a syringe made of glass, quartz or plastic, optionally filled with beads or granules to enlarge the internal surface area of the syringe (Orthogen 1) and/or utilising an inducer (Orthogen 2). Compared to recombinant technology, the Orthogen methods seek to provide a simple and inexpensive process for the production of proteins in blood by collecting blood from a patient and incubation of the blood sample to produce therapeutic proteins in the blood. Blood containing the therapeutic proteins can then be administered to a patient. In practice, the syringe sold commercially by Orthogen AG requires specialist apparatus to carry out the Orthogen methods. This means a clinic wishing to offer Orthogen’s methods requires significant capital outlay to establish, which cost inevitably flows through to the cost to the patient.
It is an aim of an embodiment of the present invention to provide an alternative to the Orthogen methods which does not require specialist equipment.
It is a further aim of an embodiment of the present invention to provide a method for increasing cytokine production in blood on a commercial scale.
SUMMARY A first aspect provides a method of producing a therapeutically active protein in a blood sample, the method comprising the step of incubating the blood sample in a blood collection or storage device containing one or more substrates, the one or more substrates having a density less than that of erythrocytes and greater than that of plasma or serum and being capable of floating in the blood sample.
Under the influence of gravity or centrifugal force, blood spontaneously sediments into three layers. At equilibrium the top, low-density layer is a straw-coloured clear fluid called plasma. Plasma is a water solution of salts, metabolites, peptides, and many proteins ranging from small (insulin) to very large (complement components).
The bottom, high-density layer is a deep red viscous fluid comprising anuclear red blood cells (erythrocytes) specialized for oxygen transport. The relative volume of whole blood that consists of erythrocytes is called the hematocrit, and in normal human beings can range from about 38% to about 54%.
The intermediate layer is the smallest, appearing as a thin white band on top the erythrocyte layer and below the plasma, and is called the buffy coat. The buffy coat itself has two major components, nucleated leukocytes (white blood cells) and anuclear smaller bodies called platelets (or thrombocytes).
In the Orthogen methods, the granules or beads lie at the bottom of the syringe and thus are mainly in contact with the erythrocyte layer. The inventors proposed that it would be beneficial to have the erthyrocytes initially exposed to granules or beads (substrates) which are then located at the plasma/buffy coat interface upon separation of layers. Using substrates of a suitable density to float at this interface the inventors were able to produce more (weighted mean) of IL-1 Ra than the control Orthogen method 1 or substantially more of IL-1Ra using a standard blood collection or storage vessel (not containing a substrate). The inventors also identified increased prointerleukin 1-beta (IL-Ιβ), Interleukin 1 Receptor Antagonist (IL-1Ra), Interleukin 2 (IL-2), Interleukin 4 (IL-4), Interleukin 5 (IL-5), Interleukin 6 (IL-6), Interleukin 7 (IL-7), Interleukin 8 (IL-8), Interleukin 9 (IL-9), Interleukin 10 (IL-10), Interleukin 12 (IL-12), Interleukin 13 (IL-13), Interleukin 15 (IL-15), Interleukin 17 (IL-17), Eotaxin 1, Fibroblast Growth Factor-beta (FGFb), Vascular Endothelial Growth Factor (VEGF), Granulocyte Stimulating Growth Factor (G-CSF), Granulocyte Macrophage Stimulating Growth Factor (GM-CSF), Platelet Derived Growth Factor (PDGF), Macrophage Inflammatory Protein 1a (MIP-1a), Macrophage Inflammatory Protein 1β (ΜΙΡ-1β),
Monocyte Chemoattractant Protein-1 (MCP-1), Interferon gamma (IFN-γ), Interferon gamma induced protein (IP-10), Regulated on Activation, Normal T Cell Expressed and Secreted (RANTES), Tumour Necrosis Factor alpha (TNF-α) and immunoglobulins. The Orthogen method is only disclosed as producing IL-4, IL-10, soluble TNF-type I, soluble TNF-type II and IL-1 ra. A second aspect provides an apparatus for producing a therapeutically active protein in a blood sample, the apparatus comprising a blood collection or blood storage device containing one or more substrates, the one or more substrates having a density less than that of erythrocytes and greater than that of plasma or serum and being capable of floating in the blood sample.
In one embodiment the method of the first aspect modulates the concentration of other proteins in the blood sample. The method may increase or decrease the concentration of one or more other proteins in the blood sample. A third aspect provides a method for treating a subject in need thereof with a therapeutic protein, the method comprising incubating a blood sample in a blood collection or storage device containing one or more substrates, the one or more substrates having a density less than that of erythrocytes and greater than that of plasma or serum and being capable of floating in the blood sample, for a time sufficient to produce a therapeutic protein and administering the blood sample to the subject.
In one embodiment the subject has rheumatism, osteoarthritis and/or a back disorder or exhibits symptoms thereof.
In one embodiment of the first, second or third aspect the therapeutic protein is interleukin 1 receptor antagonist (IL-1 Ra), prointerleukin 1-beta (IL-Ιβ), Interleukin 2 (IL-2), Interleukin 4 (IL-4), Interleukin 5 (IL-5), Interleukin 6 (IL-6), Interleukin 7 (IL-7), Interleukin 8 (IL-8), Interleukin 9 (IL-9), Interleukin 10 (IL-10), Interleukin 12 (IL-12), Interleukin 13 (IL-13), Interleukin 15 (IL-15), Interleukin 17 (IL-17), Eotaxin 1, Fibroblast Growth Factor-beta (FGFb), Vascular Endothelial Growth Factor (VEGF), Granulocyte Stimulating Growth Factor (G-CSF), Granulocyte Macrophage Stimulating Growth Factor (GM-CSF), Platelet Derived Growth Factor (PDGF), Macrophage Inflammatory Protein 1a (MIP-1a), Macrophage Inflammatory Protein 1β (ΜΙΡ-1β), Monocyte Chemoattractant Protein-1 (MCP-1), Interferon gamma (IFN-γ), Interferon gamma induced protein (IP-10), Regulated on Activation, Normal T Cell Expressed and Secreted (RANTES), Tumour Necrosis Factor alpha (TNF-α) and one or more immunoglobulins.
In one embodiment the substrate is capable of floating in the buffy coat of the blood sample.
In one embodiment the blood administered to the subject is their own blood or a fraction thereof (autologous treatment). A fourth aspect provides a method for producing a therapeutically active protein in a blood sample, the method comprising incubating the blood sample in a blood collection or storage device containing one or more substrates, the one or more substrates comprising silicates material comprising minerals or other anionic species.
In one embodiment the silicates material is selected from one or more of silicon dioxide, silicic acid gel, precipitate silicon dioxide, silica gel, hydrous silica, hydrated silicic acid or poylsilicic acid gels of the general formula H2n+2Sin03n+i.mH20.
In one embodiment the substrate is coated with an inert amorphous silicate material comprising one or more of phyllosilicates, kaolin, celite, bentonite, attapulgite and beidellite.
The inventors have found that use of substrates of silicates material provides more (weighted mean) of IL-1Ra than the control Orthogen method 1 or substantially more of IL-1Ra using a standard blood collection or storage vessel (not containing a substrate). The inventors also identified increased prointerleukin 1-beta (IL-Ιβ), Interleukin 1 Receptor Antagonist (IL-1Ra), Interleukin 2 (IL-2), Interleukin 4 (IL-4), Interleukin 5 (IL-5), Interleukin 6 (IL-6), Interleukin 7 (IL-7), Interleukin 8 (IL-8), Interleukin 9 (IL-9), Interleukin 10 (IL-10), Interleukin 12 (IL-12), Interleukin 13 (IL-13), Interleukin 15 (IL-15), Interleukin 17 (IL-17), Eotaxin 1, Fibroblast Growth Factor-beta (FGFb), Vascular Endothelial Growth Factor (VEGF), Granulocyte Stimulating Growth Factor (G-CSF), Granulocyte Macrophage Stimulating Growth Factor (GM-CSF), Platelet Derived Growth Factor (PDGF), Macrophage Inflammatory Protein 1a (MIP-1a), Macrophage Inflammatory Protein 1β (ΜΙΡ-1β),
Monocyte Chemoattractant Protein-1 (MCP-1), Interferon gamma (IFN-γ), Interferon gamma induced protein (IP-10), Regulated on Activation, Normal T Cell Expressed and Secreted (RANTES), Tumour Necrosis Factor alpha (TNF-α) and one or more immunoglobulins. The Orthogen method is only disclosed as producing IL-4, IL-10, soluble TNF-type I, soluble TNF-type II and IL-1 ra.
The inventors propose that the silicates substrate increases the surface area in contact with and interacting with the blood cells. A fifth aspect provides an apparatus for producing a therapeutically active protein in a blood sample, the apparatus comprising a blood collection or storage device containing one or more substrates comprising silicates material comprising minerals or other anionic species.
In one embodiment the silicates material is selected from one or more of silicon dioxide, silicic acid gel, precipitate silicon dioxide, silica gel, hydrous silica, hydrated silicic acid or poylsilicic acid gels of the general formula H2n+2Sin03n+i.mH20.
In one embodiment the substrate is coated with an inert amorphous silicate material comprising one or more of phyllosilicates, kaolin, celite, bentonite, attapulgite and beidellite. A sixth aspect provides a method for treating a subject in need thereof with a therapeutic protein, the method comprising incubating a blood sample in a blood collection or storage device containing one or more substrates comprising silicates material comprising minerals or other anionic species.
In one embodiment the silicates material is selected from one or more of silicon dioxide, silicic acid gel, precipitate silicon dioxide, silica gel, hydrous silica, hydrated silicic acid or poylsilicic acid gels of the general formula H2n+2Sin03n+i.mH20.
In one embodiment the substrate is coated with an inert amorphous silicate material comprising one or more of phyllosilicates, kaolin, celite, bentonite, attapulgite and beidellite.
In one embodiment the subject has rheumatism, osteoarthritis and/or a back disorder or exhibits symptoms thereof.
In one embodiment of the fourth, fifth or sixth aspect the therapeutic protein is interleukin 1 receptor antagonist (IL-1Ra), prointerleukin 1-beta (IL-Ιβ), Interleukin 2 (IL-2), Interleukin 4 (IL-4), Interleukin 5 (IL-5), Interleukin 6 (IL-6), Interleukin 7 (IL-7), Interleukin 8 (IL-8), Interleukin 9 (IL-9), Interleukin 10 (IL-10), Interleukin 12 (IL-12), Interleukin 13 (IL-13), Interleukin 15 (IL-15), Interleukin 17 (IL-17), Eotaxin 1, Fibroblast Growth Factor-beta (FGFb), Vascular Endothelial Growth Factor (VEGF), Granulocyte Stimulating Growth Factor (G-CSF), Granulocyte Macrophage Stimulating Growth Factor (GM-CSF), Platelet Derived Growth Factor (PDGF), Macrophage Inflammatory Protein 1a (MIP-1a), Macrophage Inflammatory Protein 1β (ΜΙΡ-1β), Monocyte Chemoattractant Protein-1 (MCP-1), Interferon gamma (IFN-γ), Interferon gamma induced protein (IP-10), Regulated on Activation, Normal T Cell Expressed and Secreted (RANTES), Tumour Necrosis Factor alpha (TNF-α) and one or more immunoglobulins.
In one embodiment the blood administered to the subject is their own blood or a fraction thereof (autologous treatment). A seventh aspect provides an apparatus for producing a therapeutically active protein in a blood sample, the apparatus comprising a blood collection or storage device containing one or more substrates, the one or more substrates comprising material capable of adhesion to one or more blood cells.
The inventors have found that use of substrates capable of adhering to blood cells in the collection or storage device provides more (weighted mean) of IL-1 Ra than the control Orthogen method 1 or substantially more of IL-1 Ra than obtained using a standard blood collection or storage vessel (not containing a substrate). The inventors also identified increased prointerleukin 1-beta (IL-Ιβ), Interleukin 1 Receptor Antagonist (IL-1 Ra),
Interleukin 2 (IL-2), Interleukin 4 (IL-4), Interleukin 5 (IL-5), Interleukin 6 (IL-6), Interleukin 7 (IL-7), Interleukin 8 (IL-8), Interleukin 9 (IL-9), Interleukin 10 (IL-10), Interleukin 12 (IL-12), Interleukin 13 (IL-13), Interleukin 15 (IL-15), Interleukin 17 (IL-17), Eotaxin 1, Fibroblast Growth Factor-beta (FGFb), Vascular Endothelial Growth Factor (VEGF), Granulocyte Stimulating Growth Factor (G-CSF), Granulocyte Macrophage Stimulating Growth Factor (GM-CSF), Platelet Derived Growth Factor (PDGF), Macrophage Inflammatory Protein 1a (MIP-1a), Macrophage Inflammatory Protein 1β (ΜΙΡ-1β), Monocyte Chemoattractant Protein-1 (MCP-1), Interferon gamma (IFN-γ), Interferon gamma induced protein (IP-10), Regulated on Activation, Normal T Cell Expressed and Secreted (RANTES), Tumour Necrosis Factor alpha (TNF-α) and immunoglobulins. The Orthogen method is only disclosed as producing IL-4, IL-10, soluble TNF-type I, soluble TNF-type II and IL-1 ra.
The inventors propose that the blood cells may secrete cytokines in response to adhesion to the substrate.
An eighth aspect provides a method of producing a therapeutically active protein in a blood sample, the method comprising the steps of incubating a blood sample in a blood collection or storage device containing one or more substrates comprising material capable of adhesion to one or more blood cells. A ninth aspect provides a method for treating a subject in need thereof with a therapeutic protein, the method comprising incubating a blood sample in a blood collection or storage device containing one or more substrates comprising material capable of adhesion to one or more blood cells. In one embodiment the subject has rheumatism, osteoarthritis and/or a back disorder or exhibits symptoms thereof.
In one embodiment of the seventh, eighth or ninth aspect the therapeutic protein is interleukin 1 receptor antagonist (IL-1Ra), prointerleukin 1-beta (IL-Ιβ), Interleukin 2 (IL-2), Interleukin 4 (IL-4), Interleukin 5 (IL-5), Interleukin 6 (IL-6), Interleukin 7 (IL-7), Interleukin 8 (IL-8), Interleukin 9 (IL-9), Interleukin 10 (IL-10), Interleukin 12 (IL-12), Interleukin 13 (IL-13), Interleukin 15 (IL-15), Interleukin 17 (IL-17), Eotaxin 1, Fibroblast Growth Factor-beta (FGFb), Vascular Endothelial Growth Factor (VEGF), Granulocyte Stimulating Growth Factor (G-CSF), Granulocyte Macrophage Stimulating Growth Factor (GM-CSF), Platelet Derived Growth Factor (PDGF), Macrophage Inflammatory Protein 1a (MIP-1a), Macrophage Inflammatory Protein 1β (ΜΙΡ-1β), Monocyte Chemoattractant Protein-1 (MCP-1), Interferon gamma (IFN-γ), Interferon gamma induced protein (IP-10), Regulated on Activation, Normal T Cell Expressed and Secreted (RANTES), Tumour Necrosis Factor alpha (TNF-α) and/or one or more immunoglobulins.
In one embodiment the blood administered to the subject is their own blood or a fraction thereof (autologous treatment). A tenth aspect provides a method of increasing the cytokine and immunoglobulin content of a blood sample, the method comprising incubating or storing the blood sample in the apparatus of any one of the second, fifth or seventh aspects.
An eleventh aspect provides a treated blood sample from a subject, the treated blood sample comprising elevated levels of one or more therapeutically active proteins compared to a blood sample from the subject, in which the treated blood sample is provided by incubating or storing the blood sample in the apparatus of any one of the first, fourth or seventh aspects for such a time to elevate levels of one or more therapeutically active proteins in the sample.
An eleventh aspect provides a pharmaceutical or veterinary formulation comprising one or more therapeutic protein(s) produced by the first, fourth and eighth aspects.
BRIEF DESCRIPTION OF THE DRAWINGS
In the figures that follow:
Figure 1 shows a diagrammatic representation of the apparatus of the second, fifth and seventh aspects.
Figure 2 a-d shows the biochemical analysis of blood treated according to the first, fourth and eighth aspects and blood treated according to Orthogen method 1
DETAILED DESCRIPTION
The invention allows the use of standard apparatus and need not require specialist machinery. A blood collection or storage device is any apparatus suitable for collecting blood from a subject or storing such blood. In one embodiment it is a syringe. In another embodiment it is an evacuated container blood collection tube or similar, such as a vacutainer. In one embodiment it is a blood bag. In one embodiment it is tubing which connects to a blood bag or other blood storage device.
The blood collection or storage device may be made of glass, plastic, quartz, silicate or other suitable materials known in the art or a combination of such materials. In one embodiment the blood collection device is a S-Monovette Serum Blood Collection Tube from SARSTEDT AG & Co. (Sarstedtstrafte, Postfach 1220, 51582 Numbrecht, Germany)
In one embodiment of all aspects the blood collection or storage device is sterile or is sterilised before use..
The blood collection or storage device may be a 1.2-9.0 ml blood collection vessel (aspirate or evacuated container), or a blood collection bag (being comprised of PVC or non-PVC, and with volume 50 ml - 5000 ml), or glass container (vial or bottle), or culture vessel (polycarbonate, polyetylene terapthalate or polypropylene and with volume 15 ml - 1000 ml).
The substrate(s) may take up 5% of the volume of the blood collection device. In other embodiments the substrate(s) may take up 2.5, 10, 20, or up to 50% of the volume of the blood collection device.
In one embodiment the substrate(s) provide(s) a column in the blood collection or storage device capable of allowing the blood flow therethrough.
The substrate(s) having a density less than that of erythrocytes and greater than that of plasma is/are intended to be positioned at the plasma/buffy coat interface when the blood collection device contains whole blood.
At room temperature and pressure the density of blood plasma is 1025 g/ml and the density of erythrocytes is around 1125g/ml depending on the haematocrit levels. In one embodiment the substrate(s) have a density of between 1025 and 1125 g/ml. The substrate may have a density of 1030, 1035, 1040, 1045, 1050, 1055, 1060, 1065, 1070, 1075, 1080, 1085, 1090, 1095, 1100, 1105, 1110, 1115 or 1120 g/ml, with a variation in density of 1,2 or a 3 g/ml around each integer, when measured at 25°C and atmospheric pressure.
In one embodiment of the first, second or third aspects, the substrate is made of material, particularly polystyrene (approximate density 1030-1070g/ml), ABS (approximate density 1050g/ml),polyamide (approximate density 1100 g/ml), polyethylene (approximate density 0.95-1.5 g/cc), poylpropylene (approximate density 0.9 g/cc), zirconium (approximate density 3.7 g/cc), stabilised zirconium formulations (approximate density 5.8-6.0 g/cc), cellulose acetate (approximate density ~1.3 g/cc), silica (approximate density 1.8 g/cc), poylmethylmethacrylate (approximate density 1.2 g/cc), cellulose acetate (approximate density 1.3 g/cc) or silicates material (density 160- 960 g/ml) comprising comprising minerals or other anionic species. In one embodiment the silicates material is selected from one or more of silicon dioxide, silicic acid gel, precipitate silicon dioxide, silica gel, hydrous silica, hydrated silicic acid or poylsilicic acid gels of the general formula H2n+2Sin03n+i.mH20.
In one embodiment the substrate is coated with an inert amorphous silicate material comprising one or more of phyllosilicates, kaolin, celite, bentonite, attapulgite and beidellite.
The substrate of the first, second or third aspect can be any shape or size provided it can be positioned at the plasma/buffy coat interface when the blood collection device contains whole blood. In one embodiment the substrate comprises granules, spheres, hemispheres, cubes, cuboids, pyramids, cylinders, tetrahedrons, octahedrons, dodecahedrons, cones, needles, rods, prisms, balls or grains of material of the overall required density. In one embodiment the substrate comprises granules with a diameter of 0.5 to 5 mm.
The silicates material used in the substrate(s) of the fourth to sixth aspects or the material capable of adhesion to one or more blood cells used in the substrates of the seventh, eighth or ninth aspects may be coated onto the substrate such that it covers the entire or part of the surface of the substrate or form some or all of the substrate. In one embodiment the substrate comprises beads or granules of another material, e.g. glass, metal or plastics, completely or partly coated with one or more layers of the silicates material or material capable of adhesion to one or more blood cells. In one embodiment the substrate is entirely made of the silicates material or material capable of adhesion to one or more blood cells. In one embodiment the substrate comprises silicate granules.
In one embodiment the substrate(s) are irregular in shape, wherein the imperfections provide increased surface area and binding capacity.
The substrate(s) may be coated to selectively produce or block anti- or proinflammatory proteins.
The substrate(s) may be used in combination with an additive that selectively produces or blocks anti- or pro-inflammatory proteins.
In the methods of the first and fourth aspects blood in the apparatus is incubated to produce the therapeutically active protein(s) in the blood. In one embodiment incubation comprises holding the temperature of the blood sample between 20 and 40°C, preferably 37 °C over a period of 0.5 to 48 hours or more.
The therapeutic protein(s) produced by the methods of the first, fourth and eighth aspects can advantageously be modified, for example glycosylated.
In one embodiment the blood is incubated with an anticoagulant such as heparin, acid citrate dextrose solution, citrate phosphate dextrose solution with or without adening, sodium citrate or hirudin.
In one embodiment the blood enriched for the therapeutic protein can be administered to a subject in need thereof without further manipulation or the need to transfer to another container. Alternatively the blood enriched for a therapeutic protein can be fractionated to remove solid components, particularly erythrocytes, using sterile filtration or centrifugation. In one embodiment, the proposed blood collection tubes are of a size able to fit in a standard centrifuge. In one embodiment the enriched plasma/serum can be stored (at <-19 °C in accordance with regulations in Australia, at higher temperature (2-8 °C) or even lower temperature (<-78 °C)) for later use.
In one embodiment the therapeutically active protein is a cytokine.
The term "cytokine" is a generic term for proteins released by one cell population which act on another cell population as intercellular mediators. Examples of such cytokines as produced from blood cells are Interleukin 1-beta (IL-Ιβ), Interleukin 1 Receptor Antagonist (IL-1Ra), Interleukin 2 (IL-2), Interleukin 4 (IL-4), Interleukin 5 (IL-5), Interleukin 6 (IL-6), Interleukin 7 (IL-7), Interleukin 8 (IL-8), Interleukin 9 (IL-9), Interleukin 10 (IL-10), Interleukin 12 (IL-12), Interleukin 13 (IL-13), Interleukin 15 (IL-15), Interleukin 17 (IL-17), Eotaxin 1, Fibroblast Growth Factor-beta (FGFb), Vascular Endothelial Growth Factor (VEGF), Granulocyte Stimulating Growth Factor (G-CSF), Granulocyte Macrophage Stimulating Growth Factor (GM-CSF), Platelet Derived Growth Factor (PDGF), Macrophage Inflammatory Protein 1a (MIP-1a), Macrophage Inflammatory Protein 1β (ΜΙΡ-1β),
Monocyte Chemoattractant Protein-1 (MCP-1), Interferon gamma (IFN-γ), Interferon gamma induced protein (IP-10), Regulated on Activation, Normal T Cell Expressed and Secreted (RANTES), Tumour Necrosis Factor alpha (TNF-α) and/or one or more immunoglobulins.
Particularly the cytokine is a pro-inflammatory cytokine.
The subject treated by the methods of the third, sixth or ninth aspects may have rheumatoid arthritis or osteoarthritis and/or a back disorder or exhibits symptoms thereof.
The back disorder may be associated with neurological causation, such as sciatica. The blood or blood fraction enriched for the therapeutic protein may be administered to the subject by injection, for example, at a nerve root, into the joint or into the intervertebral disk.
Suitable treatments for such diseases previously involved an invertebral disk operation, cortisone treatment, or irrigation with saline or similar. While Orthogen’s methods have been used to treat these conditions the present invention provides a more cost effective solution.
The subject is preferably an animal, In one embodiment the subject is classified as a mammal, including humans, rodents (e.g., mice and rats), and monkeys; domestic and farm animals; and zoo, sports, laboratory, or pet animals, such as dogs, cats, cattle, horses, sheep, pigs, goats, rabbits, etc. In some embodiments, the mammal is selected from a human, rodent, or monkey. Similarly, “subject” for the purposes of treatment, refers to a mammalian subject, and includes both human and veterinary subjects.
Further advantageous configurations of the invention are evident from the dependent claims.
The invention will now be illustrated with reference to the following examples, which are not intended to be limiting. EXAMPLE 1
Blood Collection for Analysis.
Freshly drawn human blood was collected from each of either five or twenty (5 or 20, healthy, male and female in the age range 20-50 years, without anti-coagulants, antiinflammatories or other illness, into three tubes individually containing (a) no granules (Neutral S-monovette 9 ml, Sarstedt AG& Co.), (b) chemically modified glass granules (Orthokine EOT II, 60 ml or 10 ml, Orthogen AG) and (c) beads coated with silicates (S-monovette Serum 9 ml, Sarstedt AG& Co.). These tubes were obtained pre-sterilised from the Manufacturers (specified).
The tubes were incubated under aseptic conditions at 37 °C for 24 h or different intervals, as indicated. After incubation, each container serum was centrifuged (3500 rpm, 10 min) and the upper layer, being plasma or serum, was transferred to a sterile syringe via a sterilising grade (0.22 urn) 33 mm filter disc membrane into a sterile syringe (3 ml,
Terumo) and fitted with a sterile syringe cap (Combi Stopper, B Braun). The syringe was frozen (-21 °C ± -2 °C) for a period up to 7 days prior to analysis.
The levels of a suite of cytokines (including chemokines, interleukins and monokines) and growth factors in the plasma/serum were measured by Bio-Plex multiplex system (BioRad, USA) with assays performed to the manufacturer’s instructions. Data were graphed using Bio-Plex Data Pro and Microsoft Excel 2007.
The results are shown in Figure 2.
It can be seen from Figure 2a that the method of the invention produced more IL-6, IL-8, MIP-1a and PDGF-bb than the Orthogen method.
It can be seen from Figure 2b that the method of the invention produced more G-CSF, MCP-1, IL-1 ra, RNATES, TNF-a and IL-1 b than the Orthogen method.
It can be seen from Figure 2c that the method of the invention produced more Eotaxin, IFN-g, MIP-1b and VEGF than the Orthogen method.
It can be seen from Figure 2d that the method of the invention produced more IL-4, IL-7 and IL-13 than the Orthogen method. EXAMPLE 2
Blood Collection for Clinical Treatment.
Freshly drawn human blood was collected from patients into six (6) tubes, each containing beads coated with silicates (S-monovette Serum 9 ml, Sarstedt AG& Co.). These tubes are provided as pre-sterilised and collection ready by the Manufacturer (specified).
The tubes were incubated under aseptic conditions at 37 °C for 24 h. After incubation, each tube was centrifuged (3500 rpm, 10 min) and the upper layer, being plasma or serum, was transferred to a sterile syringe via a sterilising grade (0.22 urn) 33 mm filter disc membrane into a sterile syringe (3 ml, Terumo) and fitted with a sterile syringe cap (Combi Stopper, B Braun). The syringe was frozen (-21 °C ± -2 °C) for a period up to 6 weeks prior to clinical treatment.
Each patient was treated with weekly injections (1 injection per week for 6 weeks). The results were as follows:
Abbreviations: VAS - visual analogue score for pain KOOS - knee injury and osteoarthritis outcome score MHH - modified Harris hip score HOOS - hip dysfunction and osteoarthritis outcome score FADI - foot and ankle disability index ASES - American shoulder and elbow surgeons score OXFORD - Oxford shoulder score KNEE: Immediately After Therapy (39 patients) • Initial VAS (mean) = 5.51 • After VAS (mean) = 3.46 • Average reduction = 2.05 • Initial KOOS (mean) = 50.26 • After KOOS (mean) = 62.32 • Average increase = 12.06
KNEE: 3 month follow-up (46 patients) • Initial VAS (mean) = 5.78 • After VAS (mean) = 4.24 • Average reduction = 1.54 • Initial KOOS (mean) = 50.66 • After KOOS (mean) = 61.73 • Average increase = 11.07
HIP: Immediately After Therapy (9 patients) • Initial VAS (mean) = 6.33 • After VAS (mean) = 3.56 • Average reduction = 2.78
HIP: 3 month follow-up (11 patients) • Initial VAS (mean) = 6.55 • After VAS (mean) = 4.82 • Average reduction = 1.73 • Initial MHH (mean) = 47.82 • After MHH (mean) = 51.82 • Average increase = 4.00 • Initial HOOS (mean) = 48.43 • After HOOS (mean) = 57.28 • Average increase = 8.85
ANKLE: Immediately After Therapy (4 patients) • Initial VAS (mean) = 4.00 • After VAS (mean) = 2.00 • Average reduction = 2.00 • Initial FADI (mean) = 66.83 • After FADI (mean) = 75.23 • Average increase = 8.40
ANKLE: 3 month follow-up (5 patients) • Initial VAS (mean) = 4.4 • After VAS (mean) = 3.6 • Average reduction = 0.8 • Initial FADI (mean) = 64.8 • After FADI (mean) = 69.1 • Average increase = 4.26
SHOULDER Immediately After Therapy (4 patients) • Initial VAS (mean) = 5.00 • After VAS (mean) = 4.75 • Average reduction = 0.25 • Initial ASES (mean) = 37.92 • After ASES (mean) = 46.25 • Average increase = 8.33 • Initial HOOS (mean) = 24.75 • After HOOS (mean) = 27.75 • Average increase = 3.00
SHOULDER 3 month follow-up (7 patients) • Initial VAS (mean) = 5.57 • After VAS (mean) = 4.00 • Average reduction = 1.57 • Initial ASES (mean) = 47.86 • After ASES (mean) = 62.13 • Average increase = 14.27 • Initial HOOS (mean) = 28.29 • After HOOS (mean) = 31.14 • Average increase = 2.86
Comments on the efficacy of the treatment are as follows:
Patient A: I have had noticeable improvement since having the treatment. No pain and at times I forget I have any issues with my knee. The muscle definition has also improved.
Patient B: Great improvement, it's hard to remember how much it hurt before.
Patient C: Every day I feel stronger with gradual improvement to my hips, I believe that I am 100% better now than what I was before starting the treatment and for that I sincerely thank you
Patient D: Seems to be improving steadily. Less than 25% of the pain I experienced prior to the injection. I acknowledge that it will never be as good as when I was young and I will always have some knee pain, but the improvement since the injections is fantastic.
Patient E: Very happy with how knees are, much improvement.
Patient F: A vast improvement in both my knees since my last injection in April. I have a little bit of swelling and pain is minimal but find that climbing stairs and getting off vehicles are hard for me and cannot walk too far.
Patient F: Knee shows definite improvement compared to my untreated knee. Better range of movement and less pain.
Patient G: I was taking anti-inflammatory pills nearly every day before the treatment and now I take one or two a week depending on what activities I am doing.
Patient H: Since the injections, I have had a lot more flexibility in the knee. A lot easier to straighten, best I have been able to do for years. The knee hurts occasionally, but only for a second or two, then goes away. The night pain has completely gone. Very happy with the results.
Patient I: Pain becoming less frequent, but am still wearing flat shoes and have begun cycling, swimming and gym work to strengthen muscles.
Claims (14)
- CLAIMS:1. A method of producing a therapeutically active protein in a blood sample, the method comprising incubating a blood sample in a blood collection or storage device containing one or more substrates, the one or more substrates having a density less than that of erythrocytes and greater than that of plasma and being capable of floating in the blood sample.
- 2. A method of producing a therapeutically active protein in a blood sample, the method comprising incubating the blood sample in a blood collection or storage device containing one or more substrates, the one or more substrates comprising silicates material.
- 3. A method of producing a therapeutically active protein in a blood sample, the method comprising incubating the blood sample in a blood collection or storage device containing one or more substrates, the one or more substrates comprising material capable of adhesion to one or more blood cells.
- 4. The method of claim 1, claim 2 or claim 3, in which the substrate comprises silicates material with a density between 1025 and 1125 g/ml at 25°C and atmospheric pressure.
- 5. The method of claim 1, claim 2 or claim 3, in which the substrate comprises plastics material, polystyrene, ABS, polyamide or silicates material comprising minerals or other anionic species.
- 6. The method of claim 6 in which the blood sample is incubated at a temperature of 20 to 40°C for 0.5 to 40 hours or more.
- 7. An apparatus for producing a therapeutically active protein in a blood sample, the apparatus comprising a blood collection or storage device containing one or more substrates, the one or more substrates (a) having a density less than that of erythrocytes and greater than that of plasma and being capable of floating in the blood sample, (b) comprising silicates material or (c) comprising material capable of adhesion to one or more blood cells.
- 8. A method for treating a subject in need thereof with a therapeutic protein, the method comprising incubating a blood sample in the blood collection or storage device of claim 7 for a time sufficient to produce a therapeutic protein and administering the blood sample to the subject,
- 9. The method of claim 8 in which the subject has rheumatism, osteoarthritis and/or a back disorder or compiaint.
- 10. The apparatus of claim 7, in which the therapeutic protein is IL-1 β, IL-1Ra, IL-2, IL-4, IL-5, IL-6, lL-7, IL-8, IL-9·,IL-10, IL-12, 11.-13,11-15, IL-17, Eotaxin 1, FGFp, VEGF, G-CSF, GM-CSF, PDGF, ΜΙΡ-1α. ΜΙΡ-1β, MCP-1, IFN-y, IP-10, RANTES, TNF-a and/or one or more immunoglobulins
- 11. The method of any one of claims 1,2, 3 or 8 in which the therapeutic protein is lL-1 β, !L-1Ra. IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, Eotaxin 1, ΡΘΡβ, VEGF, G-CSF, GM-CSF, PDGF, MlFMa, ΜΙΡ-1β, MCP-1, IFN-γ, IP-10, RANTES, TNF-a and/or one or more immunoglobulins.
- 12. A method of increasing the cytokine and immunoglobulin content of a blood sample, the method comprising incubating or storing the blood sample in the blood collection or storage vessel of claim 1.
- 13. A treated blood sample from a subject, the treated blood sample comprising elevated levels of one or more therapeutically active proteins compared to a blood sample from the subject, in which the treated blood sample is provided by incubating or storing the blood sample in the apparatus of claim 7 for such a time to elevate levels of one or more therapeutically active proteins in the sample.
- 14. A pharmaceutical or veterinary formulation comprising one or more therapeutic protein(s) produced by the method of any one of claims 1,2,3 or 8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014361728A AU2014361728A1 (en) | 2013-12-09 | 2014-12-09 | Apparatus for producing therapeutically active proteins in blood and uses thereof |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2013904778 | 2013-12-09 | ||
| AU2013904778A AU2013904778A0 (en) | 2013-12-09 | Apparatus for producing therapeutically active proteins and uses thereof | |
| AU2014361728A AU2014361728A1 (en) | 2013-12-09 | 2014-12-09 | Apparatus for producing therapeutically active proteins in blood and uses thereof |
| PCT/AU2014/001111 WO2015085348A1 (en) | 2013-12-09 | 2014-12-09 | Apparatus for producing therapeutically active proteins in blood and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2014361728A1 true AU2014361728A1 (en) | 2016-06-02 |
Family
ID=53370357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014361728A Abandoned AU2014361728A1 (en) | 2013-12-09 | 2014-12-09 | Apparatus for producing therapeutically active proteins in blood and uses thereof |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2014361728A1 (en) |
| WO (1) | WO2015085348A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022148998A1 (en) * | 2021-01-11 | 2022-07-14 | Ghanbari Ahmad | Interleukin-1 receptor antagonist (il-1ra) preparation kit in closed system |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU739517B2 (en) * | 1997-08-16 | 2001-10-11 | Orthogen Gentechnologie Gmbh | A method for inducing therapeutically-effective proteins |
| DE19903876B4 (en) * | 1999-02-01 | 2006-09-28 | Orthogen Gentechnologie Gmbh | Process for the in vitro formation and accumulation of interleukin-1 receptor antagonists |
| DE102006005016A1 (en) * | 2006-02-03 | 2007-08-16 | Orthogen Ag | Conditioned blood composition and process for its preparation |
| PL2259774T3 (en) * | 2008-02-27 | 2013-04-30 | Biomet Biologics Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
| US8460227B2 (en) * | 2008-11-17 | 2013-06-11 | Arthrex, Inc. | Cytokine concentration system |
| AU2010237191A1 (en) * | 2009-04-07 | 2011-11-03 | Velin-Pharma A/S | Method and device for treatment of conditions associated with inflammation or undesirable activation of the immune system |
| US9950035B2 (en) * | 2013-03-15 | 2018-04-24 | Biomet Biologics, Llc | Methods and non-immunogenic compositions for treating inflammatory disorders |
| US10208095B2 (en) * | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
-
2014
- 2014-12-09 WO PCT/AU2014/001111 patent/WO2015085348A1/en not_active Ceased
- 2014-12-09 AU AU2014361728A patent/AU2014361728A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015085348A1 (en) | 2015-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Basheer et al. | Role of inflammatory mediators, macrophages, and neutrophils in glioma maintenance and progression: mechanistic understanding and potential therapeutic applications | |
| Yli-Karjanmaa et al. | Topical administration of a soluble TNF inhibitor reduces infarct volume after focal cerebral ischemia in mice | |
| CN104959120B (en) | Inflammatory factor adsorbing agent for blood perfusion and preparation method | |
| Sugawara et al. | Increase in IGF-1 expression in the injured infraorbital nerve and possible implications for orofacial neuropathic pain | |
| Durand et al. | Effect of comedications and endotoxins on mesenchymal stem cell secretomes, migratory and immunomodulatory capacity | |
| Obeagu et al. | GATA-1 and Hematopoietic Stem Cell Maintenance in HIV: Mechanisms and Implications | |
| JP2016053035A (en) | Therapeutic methods for treating inflammation and immune system disorders | |
| Segabinazzi et al. | Three manual noncommercial methods to prepare equine platelet-rich plasma | |
| Obeagu et al. | GATA-1 as a Modulator of Immune Responses in HIV-Infected Individuals: Implications for Disease Pathogenesis and Therapeutic Interventions | |
| Obeagu et al. | GATA-1 and Hematopoietic Stem Cell Quiescence in HIV: Implications for Therapy | |
| Obeagu et al. | Role of GATA-1 in Megakaryopoiesis and Thrombopoiesis During HIV Infection: Molecular Insights and Therapeutic Implications | |
| AU2014361728A1 (en) | Apparatus for producing therapeutically active proteins in blood and uses thereof | |
| Obeagu et al. | The impact of obesity on overall survival in leukemia patients living with HIV: a review | |
| Park et al. | Impact of obesity on the IL-6 immune marker and Th17 immune cells in C57BL/6 mice models with imiquimod-induced psoriasis | |
| Rühle et al. | Depletion of Ly6G-expressing neutrophilic cells leads to altered peripheral T-cell homeostasis and thymic development in neonatal mice | |
| Obeagu et al. | Modulation of L-selectin Expression in Tuberculosis-HIV Coinfection: Implications for Disease Control | |
| CN109562130A (en) | Compositions for use in biological systems and methods of making and using the same | |
| Chen et al. | Macrophage activation syndrome in sepsis: from pathogenesis to clinical management | |
| Obeagu et al. | Role of L-selectin in Tuberculosis-HIV Coinfection: Implications for Immune Activation and Dysfunction | |
| CN106256374A (en) | Pharmaceutical composition containing stem cell metabolite and preparation method thereof | |
| EP3175920A1 (en) | Method and devices for producing serum | |
| RU2617537C1 (en) | System for autologous serum obtaining | |
| Hafez et al. | Cytokine gene expression in rheumatic fever | |
| CN118178475B (en) | Application of Lacticaseibacillus paracasei HNU502 in the preparation of products for alleviating side effects of antibiotics | |
| Obeagu et al. | Unveiling the Role of GATA-1 in Hematopoietic Stem Cell Function in HIV: Therapeutic Implications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |